SEHK:9969Biotechs
Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?
InnoCare Pharma (SEHK:9969) is back in focus after new clinical data showed its BTK inhibitor orelabrutinib was well tolerated and clinically effective in a large Phase IIb study for systemic lupus erythematosus.
See our latest analysis for InnoCare Pharma.
Alongside the positive lupus data, InnoCare Pharma has also started dosing patients in China with its CDH17 targeted ADC ICP-B208. The stock’s recent momentum reflects this, with a 1 month share price return of 34.55% but a 1 year total...